🔎 Trials Near Me

መነሻ › በሂስቶሎጂክ ዓይነት የተከፋፈሉ ኒዕፕላዝምስ › ፍሎሪዳ

በፍሎሪዳ ለበሂስቶሎጂክ ዓይነት የተከፋፈሉ ኒዕፕላዝምስ የሚደረጉ ክሊኒካዊ ጥናቶች

ለበሂስቶሎጂክ ዓይነት የተከፋፈሉ ኒዕፕላዝምስ የሚደረጉ 6 ጥናቶች በፍሎሪዳ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በፍሎሪዳ ውስጥ ያሉ ከተሞች

Official study text (English)

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

  • University of Florida, Gainesville
  • Mount Sinai Medical Center of Florida, Inc., Miami
  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT05874921

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

  • Moffitt Cancer Center, Tampa
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07075185

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Clermont Oncology Center, Clermont
  • Mid Florida Hematology and Oncology Center, Orange City
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁላይ 2026 · NCT04198766

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Moffitt Cancer Center, Tampa
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ጁላይ 2026 · NCT07216443

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

  • Clermont Oncology Center, Clermont
  • Oncology & Hematology Associates of West Broward, Coral Springs
  • Helios Clinical Research, Fort Lauderdale
  • እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ጁን 2026 · NCT06463665

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • Memorial Healthcare System, Hollywood
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ27 ሜይ 2026 · NCT03093116

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።